SENTRY Trials: Dr. Nikolai Podoltsev on Treatment Doublets for JAK inhibitor-Naïve Myelofibrosis

Blood Cancers Today spoke with Nikolai Podoltsev, MD, PhD, of Yale School of Medicine, on new options for treating Janus kinases (JAK) inhibitor-naïve myelofibrosis.

He described results from the phase 1 SENTRY trial (XPORT-MF-034), which evaluated 60mg of selinexor monotherapy plus ruxolitinib in 12 patients with JAK Inhibitor-naïve myelofibrosis. At week 24, spleen response reduction of 35% or greater was observed in 92% of patients. The phase 3 trial will randomize patients to ruxolitinib plus placebo or selinexor plus placebo.

Finally, Dr. Podoltsev described his hopes for the future of myelofibrosis treatment.

“We’re in the era when we’re actively exploring doublets in the frontline treatment of patients with myelofibrosis who are high risk and who are symptomatic,” he said. “I hope that one of these doublets is going to be approved one day.”